Thomas Witzig, MD
Hematology · Rochester, MNNPI 1508846791
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,838 of the $53,602 with a category attached, or 66.9%. 10 manufacturers reported payments, led by Genmab U.S., Inc. at 32.4% of the total. Reporting peaked in 2019 at $19,017 and has fallen 99.8% since, to $43 in 2025. Among hematology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $1140.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genmab U.S., Inc.$17K
- Incyte Corporation$10K
- ADC Therapeutics America, Inc.$10K
- Amgen$6K
- Genentech, Inc.$6K
- Karyopharm Therapeutics Inc.$2K
- plus $3K from 4 others
Across 16 payments — averaging $13,089 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acerta Pharma LLC$93K
- Novartis$52K
- Acrotech Biopharma Inc.$39K
- Bristol Myers Squibb$26K
What the payments were for
- Consulting fees$35,83867%
- Speaking & faculty fees$2,6145%
- Travel & lodging$14,11926%
- Food & beverage$9882%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genmab U.S., Inc. | 15 | $17,382 |
| Incyte Corporation | 6 | $9,608 |
| ADC Therapeutics America, Inc. | 4 | $9,548 |
| Amgen | 9 | $6,024 |
| Genentech, Inc. | 5 | $5,873 |
| Karyopharm Therapeutics Inc. | 1 | $2,295 |
| Gilead | 1 | $1,980 |
| Bristol Myers Squibb | 3 | $395 |
| F. Hoffmann-la Roche AG | 1 | $319 |
| AstraZeneca | 2 | $178 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,602 in reported general payments places this provider in the 90th percentile of 111 hematology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 15 | $211,447 |
| Acyclovir | 66 | $747 |
| Prednisone | 42 | $207 |
| Prochlorperazine Maleate | 13 | $163 |
| Ondansetron Hcl | 16 | $114 |
| Gabapentin | 12 | $62 |
| Pantoprazole Sodium | 13 | $61 |
| Olanzapine | 12 | $61 |
Paid to pharmacies, not to this prescriber.
Other hematology in Rochester
- Shaji KumarRochester$452K
- Yi LinRochester$365K
- David DingliRochester$299K
- Morie GertzRochester$261K
- Grzegorz NowakowskiRochester$235K
- Sameer ParikhRochester$151K
- Lindsey RoekerRochester$106K
- Mark LitzowRochester$99K
- Angela DispenzieriRochester$87K
- Prashant KapoorRochester$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.